Bengaluru: Mersana Therapeutics Inc stated on Monday that the U.S. drug regulator had positioned an early-stage trial testing its experimental cancer drug after the loss of life of a participant.
The firm stated the loss of life was of a affected person enrolled on the preliminary dose stage within the dose escalation portion. The research was testing the corporate’s XMT-2056 candidate.
The firm is now centered on analyzing the loss of life and “contemplate potential subsequent steps for growth,” Chief Executive Officer Anna Protopapas stated in a press release.
The firm will proceed to make progress with the opposite cancer drug candidate UpRi and XMT-1660 scientific trials.
Shares of Mersana have been halted earlier than the bell.
Follow and join with us on Twitter, Facebook, Linkedin, Youtube
